Temporal association between COVID-19 vaccination and Raynaud's phenomenon: A case series.

IF 4.8 4区 医学
Human Vaccines & Immunotherapeutics Pub Date : 2023-12-31 Epub Date: 2023-04-17 DOI:10.1080/21645515.2023.2199653
Marcus Lisy, Nikolaus Urban, Sophie Brunner-Ziegler, Benedikt Weber, Wolfgang M Bauer, Eva Dassler, Renate Koppensteiner, Alessandra Handisurya
{"title":"Temporal association between COVID-19 vaccination and Raynaud's phenomenon: A case series.","authors":"Marcus Lisy, Nikolaus Urban, Sophie Brunner-Ziegler, Benedikt Weber, Wolfgang M Bauer, Eva Dassler, Renate Koppensteiner, Alessandra Handisurya","doi":"10.1080/21645515.2023.2199653","DOIUrl":null,"url":null,"abstract":"<p><p>COVID-19 vaccine-related adverse events are mostly minor to moderate, and serious events are rare. Single cases of Raynaud's phenomenon (RP) in temporal proximity to COVID-19 vaccination have been reported. Demographic data, medical history, and detailed information regarding vaccination status and RP characteristics were obtained from patients with confirmed RP after COVID-19 vaccination. Fifteen participants reported the initial manifestation of RP, which occurred in 40% after the first, in 33% after the second, and in 27% after the third vaccination. RP development and occurrence of episodes were not linked to any specific vaccine type. New onset of disease was observed in 40% of the vaccinees after BNT162b2, in 33% after mRNA-1273, and in 27% after ChAdOx1 vaccination. Three out of four participants with preexisting RP prior to COVID-19 vaccination reported aggravation in frequency and intensity after immunization. Although COVID-19 vaccination is pivotal in controlling the pandemic, the observed temporal association between vaccine administration and RP occurrence warrants global activities to support pharmacovigilance for the detection of adverse reactions, one of which may include RP.</p>","PeriodicalId":13058,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"19 1","pages":"2199653"},"PeriodicalIF":4.8000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/a5/KHVI_19_2199653.PMC10116941.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Vaccines & Immunotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21645515.2023.2199653","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/4/17 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

COVID-19 vaccine-related adverse events are mostly minor to moderate, and serious events are rare. Single cases of Raynaud's phenomenon (RP) in temporal proximity to COVID-19 vaccination have been reported. Demographic data, medical history, and detailed information regarding vaccination status and RP characteristics were obtained from patients with confirmed RP after COVID-19 vaccination. Fifteen participants reported the initial manifestation of RP, which occurred in 40% after the first, in 33% after the second, and in 27% after the third vaccination. RP development and occurrence of episodes were not linked to any specific vaccine type. New onset of disease was observed in 40% of the vaccinees after BNT162b2, in 33% after mRNA-1273, and in 27% after ChAdOx1 vaccination. Three out of four participants with preexisting RP prior to COVID-19 vaccination reported aggravation in frequency and intensity after immunization. Although COVID-19 vaccination is pivotal in controlling the pandemic, the observed temporal association between vaccine administration and RP occurrence warrants global activities to support pharmacovigilance for the detection of adverse reactions, one of which may include RP.

Abstract Image

Abstract Image

新冠肺炎疫苗接种与雷诺现象的时间关联:一个病例系列。
新冠肺炎疫苗相关不良事件大多为轻度至中度,严重事件罕见。据报道,在新冠肺炎疫苗接种时间附近出现雷诺现象(RP)的单个病例。从新冠肺炎疫苗接种后确诊RP的患者中获得人口统计学数据、病史以及有关疫苗接种状态和RP特征的详细信息。15名参与者报告了RP的最初表现,第一次接种后40%、第二次接种后33%和第三次接种后27%出现RP。RP的发展和发作与任何特定的疫苗类型无关。在BNT162b2接种后,40%的接种者观察到新发疾病,在mRNA-1273接种后,33%的接种者和在ChAdOx1接种后,27%的接种者出现新发疾病。新冠肺炎疫苗接种前已有RP的参与者中,四分之三的人报告免疫接种后的频率和强度加重。尽管新冠肺炎疫苗接种在控制大流行方面至关重要,但观察到的疫苗接种与RP发生之间的时间关联保证了开展全球活动,支持药物警戒以检测不良反应,其中之一可能包括RP。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Human Vaccines & Immunotherapeutics
Human Vaccines & Immunotherapeutics BIOTECHNOLOGY & APPLIED MICROBIOLOGY-IMMUNOLOGY
自引率
8.30%
发文量
0
审稿时长
1 months
期刊介绍: (formerly Human Vaccines; issn 1554-8619) Vaccine research and development is extending its reach beyond the prevention of bacterial or viral diseases. There are experimental vaccines for immunotherapeutic purposes and for applications outside of infectious diseases, in diverse fields such as cancer, autoimmunity, allergy, Alzheimer’s and addiction. Many of these vaccines and immunotherapeutics should become available in the next two decades, with consequent benefit for human health. Continued advancement in this field will benefit from a forum that can (A) help to promote interest by keeping investigators updated, and (B) enable an exchange of ideas regarding the latest progress in the many topics pertaining to vaccines and immunotherapeutics. Human Vaccines & Immunotherapeutics provides such a forum. It is published monthly in a format that is accessible to a wide international audience in the academic, industrial and public sectors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信